Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults in Therapeutic Failure or Relapse and Not Eligible for a Clinical Trial: a Project of the SFCE

NCT04477681 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT04477681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04477681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults in Therapeutic Failure or Relapse and Not Eligible for a Clinical Trial: a Project of the SFCE
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Observational
Overall status
Recruiting
Start date
April 9, 2020
Completion date
April 30, 2027
Enrollment
1,150 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric cancer